CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025.
- Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry)
- Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hereditary volume growth of 23%
- MRD volume was ~4,700 tests in the fourth quarter, up 56% quarter-over-quarter
- Data and Applications revenue of $100.4 million in the fourth quarter, representing 25.1% year-over-year growth, with Insights (data licensing) growing 69.5%, excluding the impact of the AstraZeneca warrant in Q4 of 2024
- Ended the year with over $1.1 billion in Total Remaining Contract Value and 126% Net Revenue Retention
- $759.7 million in cash and marketable securities as of December 31, 2025
- Revenue guidance of $1.59 billion for 2026 and expect full year 2026 Adjusted EBITDA of approximately $65 million
“In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space,” said Eric Lefkofsky, Founder and CEO of Tempus. “The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world.”
Fourth Quarter Summary Results:
- Revenue increased 83.0% year-over-year to $367.2 million in the fourth quarter.
- Diagnostics generated $266.9 million of revenue in the quarter, representing 121.6% year-over-year growth, with Oncology volume growth of 29% year-over-year and Hereditary volume growth of 23%.
- Data and Applications generated $100.4 million of revenue in the quarter, representing 25.1% year-over-year growth, with Insights growing 69.5% (excluding the impact of the AstraZeneca warrant in Q4 of 2024).
- Gross profit increased 94.7% year-over-year to $237.7 million, led by strong performance in Diagnostics.
- Net loss was ($54.2 million), which included $48.7 million of stock compensation expense and related employer payroll taxes in the fourth quarter, compared to a net loss of ($13.0 million) in the fourth quarter of 2024 and a net loss of ($80.0 million) in the third quarter of 2025.
- Adjusted EBITDA improved to $12.9 million in the fourth quarter, compared to ($7.8 million) in the fourth quarter of 2024 and $1.5 million in the third quarter of 2025.
Full Year 2025 Summary Results:
- Revenue increased 83.4% year-over-year to $1.3 billion in 2025.
- Diagnostics generated $955.4 million of revenue, or 111.5% year-over-year growth, with Oncology volume growth of 26% year-over-year and Hereditary volume growth of 29%.
- Data and Applications generated $316.4 million of revenue, accelerating 30.9% year-over-year, with Insights growth of 38.0%.
- Ended the year with over $1.1 billion in remaining Total Contract Value and Net Revenue Retention of 126%.
- Gross profit increased to $797.9 million, representing 109.4% growth year-over-year.
- Net loss was ($245.0 million), which included $136.3 million of stock compensation expense and related employer payroll taxes.
- Adjusted EBITDA improved $97.3 million year-over-year to ($7.4 million), even after the acquisitions of Paige AI and OneOme.
Recent Operational Highlights
- Launched Paige Predict, an AI-powered digital pathology suite that analyzes standard H&E slides to predict 123 biomarkers across 16 cancer types, helping clinicians make informed testing decisions even when tissue samples are limited, which improves Tempus’ ability to render insights across its genomic tests.
- Announced results from a new study demonstrating that Tempus’ AI-driven Immune Profile Score (IPS) test more accurately predicts immunotherapy outcomes across various cancers than conventional biomarkers, identifying potential responders—including 13% of colorectal and 17% of rare cancer patients—who would otherwise be overlooked by standard testing.
- Entered a multi-year strategic collaboration with NYU Langone Health, centered on a prospective observational study that uses serial molecular profiling to track cancer evolution and treatment resistance, with the goal of developing AI-powered diagnostic tools and personalized therapies.
- Selected by Northwestern Medicine to expand genomic testing access to oncology patients across the health system, leveraging Tempus’ full suite of DNA, RNA, liquid biopsy, and MRD tests to enable more personalized cancer care and clinical trial design.
Fourth Quarter and Full Year 2025 Financial Results
|
|
|
Three Months Ended |
|
|
Year Ended |
|
||
|
|
|
(in thousands, except percentages and per share amounts) |
|
|||||
|
|
|
(unaudited) |
|
|||||
|
Revenue |
|
$ |
367,211 |
|
|
$ |
1,271,789 |
|
|
Year-over-year growth |
|
|
83.0 |
% |
|
|
83.4 |
% |
|
Gross profit |
|
$ |
237,713 |
|
|
$ |
797,897 |
|
|
Loss from operations |
|
$ |
(61,413 |
) |
|
$ |
(252,872 |
) |
|
Net loss |
|
$ |
(54,166 |
) |
|
$ |
(245,028 |
) |
|
Adjusted EBITDA |
|
$ |
12,893 |
|
|
$ |
(7,385 |
) |
|
Net loss per share attributable to common shareholders, basic and diluted |
|
$ |
(0.30 |
) |
|
$ |
(1.41 |
) |
|
Non-GAAP net loss per share |
|
$ |
(0.04 |
) |
|
$ |
(0.61 |
) |
Financial Outlook and Guidance
Tempus is providing full year 2026 revenue guidance of approximately $1.59 billion, which represents ~25% annual growth. We expect 2026 Adjusted EBITDA to be ~$65 million.
For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com.
Webcast and Conference Call Information
A conference call and webcast will begin today, February 24, 2026 after market close at 4:30 p.m. Eastern Time. Interested parties may access details at:
Conference ID: 4652845
United States – New York: (646) 307-1963
USA & Canada – Toll-Free: (800) 715-9871
Live webcast: https://edge.media-server.com/mmc/p/c83akphq/
The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO and Jim Rogers, CFO, which will be discussed on the conference call and webcast.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Non-GAAP Financial Measures
In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents adjusted non-GAAP financial measures.
Non-GAAP gross profit is defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”). Non-GAAP gross margin is defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue. Non-GAAP operating expenses are calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, amortization of intangibles due to acquisition, and franchise taxes related to our IPO. Non-GAAP loss from operations is defined as loss from operations, adjusted to exclude (i) stock-based compensation expense, (ii) employer payroll tax related to stock-based compensation expense, (iii) acquisition-related expenses, (iv) franchise taxes related to our IPO, and (v) amortization of intangibles due to acquisition. Non-GAAP net loss is defined as net loss, adjusted to exclude (i) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (ii) stock-based compensation expense, (iii) employer payroll tax related to stock-based compensation expense, (iv) acquisition-related expenses, (v) amortization of intangibles due to acquisition, (vi) losses from equity method investments, (vii) (benefit from) provision for income taxes, (viii) the payment of $2.3 million of our Series G-4 convertible preferred stock in connection with the initial public offering (the “G-4 Special Payment”), (ix) franchise taxes related to our IPO, (x) other tax expense, (xi) loss on debt extinguishment, and (xii) amortization of deferred other income from our IP License Agreement with SB Tempus. Non-GAAP net loss per share is defined as non-GAAP net loss divided by weighted average common shares outstanding, basic and diluted.
Adjusted EBITDA is defined as net loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) (benefit from) provision for income taxes, (v) losses from equity method investments, (vi) changes in fair value of our warrant liability, warrant asset, marketable equity securities, contingent consideration liabilities and indemnity-related holdback liabilities, (vii) stock-based compensation expense, (viii) employer payroll tax related to stock-based compensation expense, (ix) acquisition-related expenses, (x) the G-4 Special Payment, (xi) amortization of deferred other income from our IP License Agreement with SB Tempus, (xii) franchise taxes related to our IPO, (xiii) other tax expense and (xiv) loss on debt extinguishment.
Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non-GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.
Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net loss and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods, and could significantly impact future financial results.
Other Key Metrics
Total Remaining Contract Value (TCV) is equal to the total potential value of signed contracts and assumes the exercise of all contract options, all discretionary opt-ins, and no early termination. Remaining TCV excludes any revenue recognized to date on these contracts or any future adjustments made to the contractual value as a result of amendments or terminations.
Net Revenue Retention compares the annual Insights product revenue generated from all customers that made an Insights purchase in one year to the annual Insights product revenue generated from the same cohort of customers in the subsequent year.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ expected financial results for 2026; and Tempus ability to drive significant growth over the next several years and enhance the lives of millions of patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus’ ability to realize the expected benefits of the acquisition of Paige AI, Ambry Genetics and Deep 6 AI; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, trade tensions and tariffs, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“the SEC”) on February 24, 2026. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
|
Tempus AI, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except per share amounts) |
||||||||||||
|
|
|
Year Ended December 31, |
|
|||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
|
Net revenue |
|
|
|
|
|
|
|
|
|
|||
|
Diagnostics |
|
$ |
955,381 |
|
|
$ |
451,749 |
|
|
$ |
363,022 |
|
|
Data and applications(1) |
|
|
316,408 |
|
|
|
241,649 |
|
|
|
168,800 |
|
|
Total net revenue |
|
$ |
1,271,789 |
|
|
$ |
693,398 |
|
|
$ |
531,822 |
|
|
Cost and operating expenses |
|
|
|
|
|
|
|
|
|
|||
|
Cost of revenues, diagnostics |
|
|
386,102 |
|
|
|
243,467 |
|
|
|
189,165 |
|
|
Cost of revenues, data and applications |
|
|
87,790 |
|
|
|
68,818 |
|
|
|
56,482 |
|
|
Technology research and development |
|
|
146,107 |
|
|
|
167,519 |
|
|
|
95,155 |
|
|
Research and development |
|
|
172,924 |
|
|
|
149,325 |
|
|
|
90,343 |
|
|
Selling, general and administrative |
|
|
731,738 |
|
|
|
755,351 |
|
|
|
296,760 |
|
|
Total cost and operating expenses |
|
|
1,524,661 |
|
|
|
1,384,480 |
|
|
|
727,905 |
|
|
Loss from operations |
|
$ |
(252,872 |
) |
|
$ |
(691,082 |
) |
|
$ |
(196,083 |
) |
|
Interest income |
|
|
12,628 |
|
|
|
11,084 |
|
|
|
7,601 |
|
|
Interest expense |
|
|
(70,267 |
) |
|
|
(53,653 |
) |
|
|
(46,869 |
) |
|
Loss on debt extinguishment |
|
|
(12,034 |
) |
|
|
— |
|
|
|
— |
|
|
Other income, net |
|
|
31,447 |
|
|
|
32,336 |
|
|
|
21,822 |
|
|
Loss before benefit from (provision for) income taxes |
|
$ |
(291,098 |
) |
|
$ |
(701,315 |
) |
|
$ |
(213,529 |
) |
|
Benefit from (provision for) income taxes |
|
|
51,684 |
|
|
|
(266 |
) |
|
|
(288 |
) |
|
Losses from equity method investments |
|
|
(5,614 |
) |
|
|
(4,228 |
) |
|
|
(301 |
) |
|
Net Loss |
|
$ |
(245,028 |
) |
|
$ |
(705,809 |
) |
|
$ |
(214,118 |
) |
|
Accretion of convertible preferred stock to redemption value |
|
|
— |
|
|
|
— |
|
|
|
(4,338 |
) |
|
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares |
|
|
— |
|
|
|
(39,347 |
) |
|
|
(44,497 |
) |
|
Cumulative undeclared dividends on Series C preferred shares |
|
|
— |
|
|
|
(1,174 |
) |
|
|
(3,011 |
) |
|
Net loss attributable to common shareholders, basic and diluted |
|
|
(245,028 |
) |
|
|
(746,330 |
) |
|
|
(265,964 |
) |
|
Net loss per share attributable to common shareholders, basic and diluted |
|
$ |
(1.41 |
) |
|
$ |
(6.23 |
) |
|
$ |
(4.20 |
) |
|
Weighted-average shares outstanding used to compute net loss per share, basic and diluted |
|
|
174,264 |
|
|
|
119,849 |
|
|
|
63,306 |
|
|
Comprehensive Loss, net of tax |
|
|
|
|
|
|
|
|
|
|||
|
Net loss |
|
$ |
(245,028 |
) |
|
$ |
(705,809 |
) |
|
$ |
(214,118 |
) |
|
Foreign currency translation adjustment |
|
|
808 |
|
|
|
89 |
|
|
|
(13 |
) |
|
Comprehensive loss |
|
$ |
(244,220 |
) |
|
$ |
(705,720 |
) |
|
$ |
(214,131 |
) |
|
(1) |
Includes related party revenue of $65,251, $4,502 and $673 for the years ended December 31, 2025, 2024 and 2023, respectively. |
|
Tempus AI, Inc. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) |
||||||||
|
|
|
December 31, 2025 |
|
|
December 31, 2024 |
|
||
|
Assets |
|
|
|
|
|
|
||
|
Current Assets |
|
|
|
|
|
|
||
|
Cash and cash equivalents |
|
$ |
604,787 |
|
|
$ |
340,954 |
|
|
Accounts receivable(1), net of allowances of $2,755 and $1,141 at December 31, 2025 and 2024, respectively |
|
|
311,170 |
|
|
|
154,819 |
|
|
Inventory |
|
|
51,724 |
|
|
|
38,386 |
|
|
Related party asset |
|
|
8,785 |
|
|
|
— |
|
|
Prepaid expenses and other current assets |
|
|
40,498 |
|
|
|
26,135 |
|
|
Marketable equity securities |
|
|
150,211 |
|
|
|
107,309 |
|
|
Total current assets |
|
$ |
1,167,175 |
|
|
$ |
667,603 |
|
|
Property and equipment, net |
|
|
89,156 |
|
|
|
58,056 |
|
|
Goodwill |
|
|
470,211 |
|
|
|
73,343 |
|
|
Intangible assets, net |
|
|
355,253 |
|
|
|
11,716 |
|
|
Investments and other assets |
|
|
21,111 |
|
|
|
8,305 |
|
|
Investment in joint venture |
|
|
86,557 |
|
|
|
91,450 |
|
|
Related party asset, less current portion |
|
|
16,215 |
|
|
|
— |
|
|
Operating lease right-of-use assets |
|
|
64,496 |
|
|
|
14,762 |
|
|
Restricted cash |
|
|
4,664 |
|
|
|
881 |
|
|
Total Assets |
|
$ |
2,274,838 |
|
|
$ |
926,116 |
|
|
|
|
|
|
|
|
|
||
|
Liabilities, Convertible redeemable preferred stock, and Stockholders’ equity |
|
|
|
|
|
|
||
|
Current Liabilities |
|
|
|
|
|
|
||
|
Accounts payable |
|
|
81,994 |
|
|
|
53,804 |
|
|
Accrued expenses |
|
|
155,370 |
|
|
|
130,407 |
|
|
Deferred revenue(2) |
|
|
92,673 |
|
|
|
75,981 |
|
|
Deferred other income |
|
|
15,955 |
|
|
|
15,955 |
|
|
Other current liabilities |
|
|
8,680 |
|
|
|
6,964 |
|
|
Operating lease liabilities |
|
|
13,355 |
|
|
|
6,459 |
|
|
Accrued data licensing fees |
|
|
4,361 |
|
|
|
1,500 |
|
|
Total current liabilities |
|
$ |
372,388 |
|
|
$ |
291,070 |
|
|
Operating lease liabilities, less current portion |
|
|
74,272 |
|
|
|
26,199 |
|
|
Convertible promissory note |
|
|
208,672 |
|
|
|
168,192 |
|
|
Other long-term liabilities |
|
|
56,600 |
|
|
|
15,980 |
|
|
Revolving credit facility |
|
|
100,000 |
|
|
|
— |
|
|
Interest payable |
|
|
12,393 |
|
|
|
70,450 |
|
|
Long-term debt, net |
|
|
202,753 |
|
|
|
267,244 |
|
|
Convertible senior notes, net |
|
|
728,078 |
|
|
|
— |
|
|
Deferred other income, less current portion |
|
|
7,977 |
|
|
|
23,932 |
|
|
Deferred revenue, less current portion |
|
|
20,379 |
|
|
|
6,710 |
|
|
Total Liabilities |
|
$ |
1,783,512 |
|
|
$ |
869,777 |
|
|
(1) |
Includes related party accounts receivable of $6,428 and $4,287 as of December 31, 2025 and 2024, respectively. |
|
(2) |
Includes related party deferred revenue of $3,938 and $0 as of December 31, 2025 and 2024, respectively. |
|
Tempus AI, Inc. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) |
||||||||
|
Commitments and contingencies (Note 7) |
|
|
|
|
|
|
||
|
Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at December 31, 2025 and 2024, respectively, no shares issued and outstanding at December 31, 2025 and 2024 |
|
$ |
— |
|
|
$ |
— |
|
|
Stockholders’ equity |
|
|
|
|
|
|
||
|
Class A Common Stock, $0.0001 par value, 1,000,000,000 shares authorized at December 31, 2025 and 2024, respectively; 173,235,428 and 157,076,972 shares issued and outstanding at December 31, 2025 and 2024, respectively |
|
|
17 |
|
|
|
16 |
|
|
Class B Common Stock, $0.0001 par value, 5,500,000 shares authorized at December 31, 2025 and 2024, respectively; 5,043,789 issued and outstanding at December 31, 2025 and 2024, respectively |
|
|
1 |
|
|
|
1 |
|
|
Non-voting Common Stock, $0.0001 par value, no shares authorized at December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025, and 2024, respectively |
|
|
— |
|
|
|
— |
|
|
Treasury Stock, 183,229 and 145,466 shares at December 31, 2025 and 2024, respectively, at cost |
|
|
(6,642 |
) |
|
|
(3,602 |
) |
|
Additional Paid-In Capital |
|
|
2,892,910 |
|
|
|
2,210,664 |
|
|
Accumulated Other Comprehensive Income |
|
|
902 |
|
|
|
94 |
|
|
Accumulated deficit |
|
|
(2,395,862 |
) |
|
|
(2,150,834 |
) |
|
Total Stockholders’ equity |
|
$ |
491,326 |
|
|
$ |
56,339 |
|
|
Total Liabilities, Convertible redeemable preferred stock, and Stockholders’ equity |
|
$ |
2,274,838 |
|
|
$ |
926,116 |
|
|
Tempus AI, Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, except per share amounts) |
||||||||||||
|
|
|
Year Ended December 31, |
|
|||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
|
Operating activities |
|
|
|
|
|
|
|
|
|
|||
|
Net loss |
|
$ |
(245,028 |
) |
|
$ |
(705,809 |
) |
|
$ |
(214,118 |
) |
|
Adjustments to reconcile net loss to net cash used in operating activities |
|
|
|
|
|
|
|
|
|
|||
|
Change in fair value of warrant liability |
|
|
— |
|
|
|
42,400 |
|
|
|
(8,000 |
) |
|
Gain on warrant termination |
|
|
— |
|
|
|
(39,100 |
) |
|
|
— |
|
|
Reversal of warrant contract asset amortization |
|
|
— |
|
|
|
(16,301 |
) |
|
|
— |
|
|
Stock-based compensation |
|
|
124,747 |
|
|
|
534,138 |
|
|
|
— |
|
|
Gain on warrant exercise |
|
|
— |
|
|
|
(173 |
) |
|
|
— |
|
|
Gain on marketable equity securities |
|
|
(16,471 |
) |
|
|
(12,110 |
) |
|
|
(9,807 |
) |
|
Loss on disposal of property and equipment |
|
|
415 |
|
|
|
— |
|
|
|
— |
|
|
Loss on debt extinguishment |
|
|
12,034 |
|
|
|
— |
|
|
|
— |
|
|
Deferred income taxes |
|
|
(52,665 |
) |
|
|
— |
|
|
|
— |
|
|
Losses from equity method investments |
|
|
5,614 |
|
|
|
4,228 |
|
|
|
301 |
|
|
Amortization of original issue discount |
|
|
4,088 |
|
|
|
1,382 |
|
|
|
1,117 |
|
|
Amortization of deferred financing fees |
|
|
484 |
|
|
|
510 |
|
|
|
510 |
|
|
Change in fair value of contingent consideration |
|
|
— |
|
|
|
72 |
|
|
|
(400 |
) |
|
Change in fair value of holdback liability |
|
|
(1,337 |
) |
|
|
— |
|
|
|
— |
|
|
Amortization of warrant contract asset |
|
|
— |
|
|
|
4,843 |
|
|
|
5,221 |
|
|
Depreciation and amortization |
|
|
102,324 |
|
|
|
37,245 |
|
|
|
33,049 |
|
|
Provision for bad debt expense |
|
|
2,558 |
|
|
|
680 |
|
|
|
1,646 |
|
|
Provision for obsolete inventory |
|
|
1,335 |
|
|
|
— |
|
|
|
— |
|
|
Amortization of finance right-of-use lease assets |
|
|
— |
|
|
|
— |
|
|
|
283 |
|
|
Change in fair value of warrant asset |
|
|
— |
|
|
|
(18,302 |
) |
|
|
(4,100 |
) |
|
Non-cash operating lease costs |
|
|
11,554 |
|
|
|
6,047 |
|
|
|
6,760 |
|
|
Minimum accretion expense |
|
|
268 |
|
|
|
197 |
|
|
|
90 |
|
|
Impairment of intangible assets |
|
|
— |
|
|
|
— |
|
|
|
7,359 |
|
|
PIK interest added to principal |
|
|
10,537 |
|
|
|
8,811 |
|
|
|
3,587 |
|
|
Change in assets and liabilities |
|
|
|
|
|
|
|
|
|
|||
|
Accounts receivable(1) |
|
|
(90,402 |
) |
|
|
(61,037 |
) |
|
|
(7,347 |
) |
|
Inventory |
|
|
(3,369 |
) |
|
|
(9,541 |
) |
|
|
(6,563 |
) |
|
Prepaid expenses and other current assets |
|
|
(1,699 |
) |
|
|
(13,683 |
) |
|
|
(6,474 |
) |
|
Investments and other assets |
|
|
(17,301 |
) |
|
|
(751 |
) |
|
|
(4,209 |
) |
|
Accounts payable |
|
|
(7,241 |
) |
|
|
(23,852 |
) |
|
|
(23,363 |
) |
|
Related party asset |
|
|
(25,000 |
) |
|
|
— |
|
|
|
— |
|
|
Deferred revenue(2) |
|
|
(6,960 |
) |
|
|
(20,942 |
) |
|
|
(26,412 |
) |
|
Deferred other income |
|
|
(15,955 |
) |
|
|
39,887 |
|
|
|
— |
|
|
Accrued data licensing fees |
|
|
2,966 |
|
|
|
(5,000 |
) |
|
|
(9,121 |
) |
|
Accrued expenses & other |
|
|
(12,844 |
) |
|
|
50,540 |
|
|
|
38,577 |
|
|
Interest payable |
|
|
14,206 |
|
|
|
15,129 |
|
|
|
15,836 |
|
|
Operating lease liabilities |
|
|
(14,948 |
) |
|
|
(8,553 |
) |
|
|
(8,761 |
) |
|
Net cash used in operating activities |
|
$ |
(218,090 |
) |
|
$ |
(189,045 |
) |
|
$ |
(214,339 |
) |
Contacts
Tempus Communications
Hanah Heintzelman
[email protected]
Tempus Investor Relations
Elizabeth Krutoholow
[email protected]
